Regulation - Sanofi, Pricing

Filter

Current filters:

SanofiPricing

Popular Filters

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

NICE recommends Sanofi’s Aubagio as new treatment option for MS

NICE recommends Sanofi’s Aubagio as new treatment option for MS

22-01-2014

In final guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

AubagioBiotechnologyGenzymeNeurologicalNorthern EuropePricingRegulationSanofiUK

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

08-01-2014

In yet another negative opinion from the German Institute for Quality and Efficiency in Health Care (IQWiG)…

AubagioGermanyNeurologicalNorthern EuropePharmaceuticalPricingRegulationSanofi

Sanofi’s Aubagio gains backing from UK’s NICE

Sanofi’s Aubagio gains backing from UK’s NICE

08-12-2013

In final draft guidance issued on Friday, the UK drugs watchdog the National Institute for Health and…

AubagioEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofiUK

UK’s NICE calls for more info on Sanofi’s Lemtrada in draft guidance

UK’s NICE calls for more info on Sanofi’s Lemtrada in draft guidance

05-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

BiotechnologyEuropeGenzymeLemtradaNeurologicalPricingRegulationSanofiUK

UK's NICE calls for more information on MS treatment Aubagio

18-09-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

AubagioBiotechnologyEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofi

UK's NICE issues negative new draft guidance on Sanofi's Zaltrap

21-06-2013

The UK's drug watchdog the National Institute for Health Care and Excellence (NICE) has issued new draft…

EuropeOncologyPharmaceuticalPricingRegulationSanofiZaltrap

UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine

11-05-2012

Confirming previous negative guidance (The Pharma Letter January 12), UK drugs watchdog the National…

AllerganBotoxEuropeJevtanaNeurologicalOncologyPharmaceuticalPricingRegulationSanofi

Some advantages seen for Sanofi’s Jevtana by Germany’s IQWiG

25-01-2012

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

EuropeJevtanaOncologyPharmaceuticalPricingRegulationSanofi

Negative NICE guidance for Sanofi prostate cancer drug

12-01-2012

The UK’s drug watchdog the National Institute for Health and Clinical Excellence (NICE), has today…

EuropeJevtanaOncologyPharmaceuticalPricingRegulationSanofi

Back to top